Dados B3 › EGIE3 × EQTL3
EGIE3 × EQTL3
Indicators
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | EGIE3 | EQTL3 | year |
|---|---|---|---|
| ROE | 21.5% | 6.5% | 2025 |
| ROIC | 13.9% | 9.3% | 2025 |
| ROA | 5.4% | 2.2% | 2025 |
| Gross margin | 46.7% | 26.1% | 2025 |
| EBIT margin | 48.7% | 15.6% | 2025 |
| Net margin | 22.2% | 4.8% | 2025 |
| Net debt/EBITDA | 3.30x | 3.90x | 2025 |
| Current ratio | 1.12x | 1.49x | 2025 |
| Revenue growth (1y) | 14.6% | 19.0% | 2025 |
| Revenue growth (5y CAGR) | 1.0% | 23.8% | 2025 |
| Piotroski F-Score | 5/9 | 5/9 | 2025 |
Point-in-time multiples
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | EGIE3 | EQTL3 | year |
|---|---|---|---|
| P/E | 14.21x | 32.35x | 2025 |
| P/B | 2.88x | 2.11x | 2025 |
| EV/EBITDA | 8.09x | 8.72x | 2025 |
| FCF yield | 4.3% | -7.6% | 2025 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-09 12:37 UTC. If this does not match /saude, you are reading a cached copy.
Sources: CVM (open data, ODbL) and B3 (COTAHIST). Not affiliated with B3 or the CVM. Not investment advice.